{"transactions":[{"id":1783994,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-09-11T09:19:33.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":35000,"price":0.3199,"value":11196.5,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (i) 8,336 shares of Common Stock held by Samuel David Gorovitz 2017 Irrevocable Trust, (ii) 8,336 shares of Common Stock held by Jeremy Paul Gorovitz 2017 Irrevocable Trust, (iii) 8,336 shares of Common Stock held by Marisa Shey Gorovitz 2017 Irrevocable Trust, (iv) 51,678 shares of Common Stock held by Elizabeth Gorovitz. Aaron Gorovitz is the trustee of the Samuel David Gorovitz 2017 Irrevocable Trust, the Jeremy Paul Gorovitz 2017 Irrevocable Trust, and the Marisa Shey Gorovitz 2017 Irrevocable Trust. Elizabeth Gorovitz is the wife of Aaron Gorovitz;"}],"balance_after":105000,"source":{"system":"sec-edgar","filing":"0001415889-23-013139","document":"form4-09112023_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000141588923013139/form4-09112023_010928.xml","form_type":"4"}},{"id":2107145,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2022-11-22T17:46:27.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":162660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for NRx Pharmaceuticals, Inc."}],"balance_after":162660,"derivative":{"exercise_price":0.75,"expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":162660},"source":{"system":"sec-edgar","filing":"0000950142-22-003244","document":"es220307157_4-gorovitz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014222003244/es220307157_4-gorovitz.xml","form_type":"4"}},{"id":2674217,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":16678,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674216,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":8336,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by the Marisa Shey Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee."}],"balance_after":8336,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674215,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":8336,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the Jeremy Paul Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee."}],"balance_after":8336,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}},{"id":2674214,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":109830,"kind":"person","name":"Gorovitz Aaron","position":1,"cik":"0001864536","reported_name":"Gorovitz Aaron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T18:47:12.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":8336,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Samuel David Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee."}],"balance_after":8336,"source":{"system":"sec-edgar","filing":"0000950142-21-001941","document":"es210157185_4-gorovitz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864536/000095014221001941/es210157185_4-gorovitz.xml","form_type":"4"}}]}